$6.19
1.90% yesterday
Nasdaq, May 09, 09:47 pm CET
ISIN
US6821431029
Symbol
OMER
Sector
Industry

Omeros Corporation Stock price

$6.18
-0.32 4.92% 1M
+1.89 44.06% 6M
-3.70 37.45% YTD
+2.62 73.60% 1Y
+3.42 123.91% 3Y
-10.81 63.63% 5Y
-14.88 70.66% 10Y
Nasdaq, Closing price Fri, May 09 2025
-0.13 2.06%
ISIN
US6821431029
Symbol
OMER
Sector
Industry

Key metrics

Market capitalization $360.33m
Enterprise Value $693.48m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-169.26m
Free Cash Flow (TTM) Free Cash Flow $-148.97m
Cash position $90.13m
EPS (TTM) EPS $-2.70
P/E forward negative
P/S forward 80.97
EV/Sales forward 155.84
Short interest 19.28%
Show more

Is Omeros Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,791 stocks worldwide.

Omeros Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Omeros Corporation forecast:

2x Buy
50%
2x Hold
50%

Analyst Opinions

4 Analysts have issued a Omeros Corporation forecast:

Buy
50%
Hold
50%

Financial data from Omeros Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.95 0.95
7% 7%
-
-0.95 -0.95
7% 7%
-
- Selling and Administrative Expenses 49 49
1% 1%
-
- Research and Development Expense 119 119
4% 4%
-
-168 -168
3% 3%
-
- Depreciation and Amortization 0.95 0.95
7% 7%
-
EBIT (Operating Income) EBIT -169 -169
3% 3%
-
Net Profit -157 -157
33% 33%
-

In millions USD.

Don't miss a Thing! We will send you all news about Omeros Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Omeros Corporation Stock News

Neutral
Business Wire
4 days ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The resubmission was classified as a Class 2 resubmission and pursua...
Neutral
Business Wire
30 days ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros' OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affecting the blood/bone ma...
Neutral
Business Wire
about one month ago
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first public presentation of its proprietary Targeted Complement Activating TherapyTM (T-CATTM) platform will occur at the European Congress on Infectious Diseases 2025 in Rome, Italy on Monday, April 14. The plenum presentation, titled Augmenting cytotoxicity of pathogen-specific antibodies which initiate comp...
More Omeros Corporation News

Company Profile

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Head office United States
CEO Gregory Demopulos
Employees 202
Founded 1994
Website www.omeros.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today